Nvidia vs. Eli Lilly: I’d Choose This Stock for the Next Decade
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.
NVIDIA (NASDAQ: NVDA | NVDA Price Prediction) and Eli Lilly (NYSE: LLY) just posted quarters that showcase two of the most powerful growth engines in the market.
NVIDIA is riding a supply-constrained AI infrastructure build. Lilly is scaling GLP-1 medicines faster than it can add factories. Both blew past estimates. Only one, in my view, has a cleaner runway for the next decade.
AI Factories Carry NVIDIA. GLP-1 Carries Lilly.
NVIDIA delivered $96.22B in Q2 FY2027 revenue, up 105.8% year over year, with Data Center alone contributing $89.02B. Blackwell Ultra is ramping, and Vera Rubin is already in full production.
CEO Jensen Huang framed the moment bluntly: “AI has reached its inflection point. It’s doing useful work. Its tokens are productive and profitable. Now, compute is revenue.” Management now guides Q3 to $108B and expects roughly 70% revenue growth in fiscal 2028, all while calling the outlook supply-constrained.
Lilly reported $22.97B in Q2 2026 revenue, up 47.7%, with Mounjaro and Zepbound combining for $14.9 billion. International momentum is real: rest-of-world grew 136% in constant currency, and China Mounjaro sales jumped 93%.
Lilly’s oral GLP-1 Foundeo expanded its U.S. prescriber base from 8,000 to 36,000 in a single quarter. Full-year revenue guidance moved up to $85B to $87B.

| Business Driver | NVIDIA | Eli Lilly |
| Main Growth Engine | Data Center compute and networking | Mounjaro, Zepbound, Foundeo |
| Revenue Growth (last Q) | +105.8% | +47.7% |
| Gross Margin | 75.0% | 85.8% |
Two Very Different Bets on the Next Decade
NVIDIA is monetizing a platform. Every gigawatt of Vera Rubin represents $40 billion in revenue opportunity, up from Blackwell’s $25 billion. Hyperscaler capex is projected to hit nearly 800 billion in 2026 and 1.3 trillion in 2027.
The risks are equally large: extreme memory pricing, $279B in supply commitments, zero China DC compute in guidance, and growing scrutiny of NVIDIA’s balance-sheet support for AI labs.
Lilly is monetizing a molecule pipeline. Retatrutide, its next-gen triple-acting weight-loss drug, produced weight loss “approaching bariatric surgery levels”, with a BLA filing planned for Q1 2027.
The company has more than 40 active phase three programs. But U.S. price fell 9% ex-rebates, and concentration in two drugs is a real vulnerability.
What Would Change My Mind
Watch NVIDIA’s Vera Rubin ramp, which management expects to reach about 20% of data center revenue in Q3. If supply loosens without demand blinking, the FY28 EPS estimate of $15.5675 could look conservative.
For Lilly, I want retatrutide’s regulatory path confirmed and Foundeo’s international launches to translate into durable share.
Why NVIDIA Stands Out for the Next Decade
For a ten-year lens, NVIDIA screens strongest. The forward P/E of 23 against triple-digit growth and a 60.4% operating margin is hard to argue with, and the platform’s optionality across networking, CPUs, robotics, and sovereign AI keeps widening.
Lilly is a magnificent business, and for lower beta (0.502 versus NVDA’s 2.217) with a real dividend, it fits a defensive growth profile better. Both are compelling on their own terms. On relative setup, the AI factory looks better positioned than the drug factory, at least until the supply-demand gap closes.
Contact [email protected] for any questions or corrections.







